Change font size

glossary
professional site
prescribing information

Home
NovoSeven^® RT Difference
Hemophilia With Inhibitors
Factor VII Deficiency
Acquired Hemophilia
Patient Resources
Life With Hemophilia

Home
Patient Resources
Stay in Touch

Stay in Touch

Thank you for your interest in NovoSeven^® RT

Now you can keep up with news and updates of importance to members of the bleeding disorders community. Just complete this form to receive helpful information from Novo Nordisk. You will also receive the NovoSeven^® RT Newsletter and information about products and services from Novo Nordisk. This form is intended for US citizens over the age of 18 years only.

* Indicates required field

First Name:* Last Name:*

E-mail:* Verify E-mail:* Password:* Verify Password:*

Address: City: State: Zip:

California Residents: You must re-enter you first and last name as well as today's date. Doing so and submitting this form will constitute your signature electronically.

First Name* Last Name* Date*

/

/

I am a: PatientCaregiver My age is: 18 - 3435 - 4950 - 6465 and older If caregiver, what is age of patient?: 0 - 1718 - 3435 - 4950 - 6465 and older What is the diagnosis of the patient?: Hemophilia with InhibitorsFactor VII Deficiency

I agree that the information I am providing may be used by Novo Nordisk or third parties working on its behalf for business purposes, including providing me with support literature and special offers, contacting me regarding research or opportunities that may be of interest to me, and marketing or advertising products, goods or services. Under no circumstances will Novo Nordisk sell, rent, or lease my personal information to others. Novo Nordisk will take appropriate measures to protect my information, and I can stop all use of my information by Novo Nordisk by calling 800-727-6500 or by clicking on the "unsubscribe" link in any future email communications. I certify that I am at least eighteen (18) years of age.*

Click to view our Disclaimer & Privacy statement.

INDICATIONS

NovoSeven^® RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

IMPORTANT SAFETY INFORMATION

The most common side effects in people taking rFVIIa were fever, bleeding, injection site reaction, joint pain, headache, hypertension, hypotension, nausea, vomiting, pain, swelling, and rash.
After taking rFVIIa, some patients have more of a risk of thrombosis, which is when a clot forms in a blood vessel and causes harm. Although the extent of this risk is not known, it is thought to be small. Some patients have conditions that may increase this risk. These include clogged arteries, blood clots that form throughout the body instead of at the place of injury, a type of blood poisoning called septicemia, and crush injury, which is when a body part is crushed or squeezed between heavy or immobile objects. Also, people taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) at the same time that they are taking NovoSeven^® RT may be at increased risk for thrombosis.
People who have ever had a bad reaction to proteins from mice, hamsters, or "bovines" (such as an ox or cow) should consult their physician prior to using NovoSeven^® RT.
Serious adverse events which may or may not have been related to the use of rFVIIa occurred in 14 of the 298 patients in the initial clinical program.
There have been no reports of rFVIIa causing bad reactions to "analgesics" (such as pain killers), "antibiotics" (the drugs used to treat infection), or "sedatives" (sleeping pills or tranquilizers).
Some patients with Factor VII deficiency have developed resistance (antibodies) to Factor VII after treatment with rFVIIa. These patients had been previously treated with human plasma and/or plasma-derived Factor VII.
Use of NovoSeven^® RT with other formulations of rFVIIa is not recommended due to potential dosing errors resulting from different concentrations.

Please click here for NovoSeven^® RT Prescribing Information

Please click here for original NovoSeven^® Prescribing Information

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
NovoSeven is a registered trademark of Novo Nordisk Health Care AG.
© 2008 Novo Nordisk Inc. 135550 June 2008

disclaimer & privacy
site map
references
contact novo nordisk